Immuno-Oncology News

July 6, 2020July 6, 2020

First-line Tislelizumab Plus Chemo Under Review in China for Advanced NSCLC

The Chinese Center for Drug Evaluation (CDE) of the National Medical Products Administration has accepted for review Beigene’s application seeking approval for tislelizumab, in combination with standard chemotherapy, as a first-line treatment for ... Read more

July 2, 2020July 2, 2020

FDA Approves Bavencio Maintenance Therapy for Advanced Bladder Cancer

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has approved Bavencio (avelumab) as a first-line maintenance therapy for people with advanced urothelial carcinoma — a type of bladder cancer — whose disease ... Read more

July 1, 2020July 1, 2020

FDA Approves Keytruda as First-line Therapy for Certain Advanced Colorectal Cancers

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line therapy for people with inoperable or metastatic colorectal cancer with specific genetic features that denote a high ... Read more

June 30, 2020July 1, 2020

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing patient-reported symptoms from cancer trials for marketed ... Read more

June 29, 2020June 30, 2020

EMA Asked to Conditionally Approve Gliovac, Cancer Vaccine, for Recurrent Glioblastoma

Immuno-Oncology News

ERC Belgium has asked the European Medicines Agency (EMA) to give conditional approval to its investigational anti-cancer vaccine Gliovac (ERC1671) for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. ... Read more

June 26, 2020June 26, 2020

FDA Approves Keytruda for Advanced Squamous Cell Skin Cancer

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a treatment for people with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) — the second most common form ... Read more

June 24, 2020June 24, 2020

Keytruda Approved in China as Second-line Therapy for Advanced Esophageal Cancers

Immuno-Oncology News

The Chinese National Medical Products Administration (NMPA) has approved Keytruda (pembrolizumab) as a second-line therapy for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors have ... Read more

June 22, 2020June 22, 2020

Imfinzi Plus Chemo Showing 2-year Survival Benefit in Advanced SCLC Study

Immuno-Oncology News

Adding Imfinzi (durvalumab) to standard chemotherapy as the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC) continues to show survival benefits sustained now for two years, updated findings ... Read more

June 18, 2020June 18, 2020

Keytruda Approved to Treat Solid Tumors With High Mutational Burden

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has conditionally approved Keytruda (pembrolizumab) for the treatment of pediatric and adult patients with inoperable or metastatic solid tumors with high tumor mutational ... Read more

June 17, 2020June 17, 2020

Bavencio Shows Benefit as 1st-line Maintenance Therapy for Bladder Cancer in Phase 3 Trial

Immuno-Oncology News

First-line maintenance therapy with Bavencio (avelumab) significantly delays disease progression or death in people with inoperable, locally advanced or metastatic urothelial carcinoma, a common type of bladder cancer, according to interim data from ... Read more

June 15, 2020June 15, 2020

Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Track

Immuno-Oncology News

TVI-Brain-1, an immunotherapy being developed by TVAX Biomedical, was given fast track designation by the U.S. Food and Drug Administration (FDA) as a potential treatment of glioblastoma multiforme, a deadly form of ... Read more

June 12, 2020June 12, 2020

FDA Approves Opdivo for Advanced Esophageal Cancer

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the treatment of people with advanced, inoperable, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) previously treated with ... Read more

June 5, 2020June 5, 2020

Tislelizumab-Chemo Combo Does Well in Advanced Squamous NSCLC Trial

Immuno-Oncology News

Adding Beigene‘s experimental therapy tislelizumab to standard first-line chemotherapy significantly delays disease progression or death in patients with advanced squamous non-small cell lung cancer (NSCLC), data from a Phase 3 ... Read more

June 3, 2020June 3, 2020

FDA Approves Tecentriq-Avastin Combo for Newly Diagnosed Advanced Liver Cancer

Immuno-Oncology News

The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of newly diagnosed patients with advanced hepatocellular carcinoma (HCC), the most ... Read more

June 1, 2020June 1, 2020

Surface, Merck Partner on SRF617-Keytruda Combo Targeting Solid Tumors

Immuno-Oncology News

Surface Oncology has entered a collaboration with Merck to investigate a combination of SRF617 and Keytruda (pembrolizumab) in patients with solid tumors, with a particular focus on individuals with gastric ... Read more